Direct cardiac actions of Ertugliflozin
Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors block renal glucose reabsorption and have shown marked cardiac protection in type 2 diabetics, and surprisingly, also in non-diabetics. However, the mechanism by which these drugs improve cardiovascular outcomes is unknown. Metabolic heart disea...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/41130 |